Literature DB >> 14967002

Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.

Teresa M Alvarez-Diez1, Jiang Zheng.   

Abstract

Earlier phase I and II clinical studies showed that 4-ipomeanol produced selective hepatotoxicity. To investigate the mechanism of bioactivation of 4-ipomeanol, we thoroughly studied the interaction of 4-ipomeanol with human cytochrome P450 3A4 (EC 1.14.14.1). 4-Ipomeanol produced a time- and concentration-dependent inactivation of P450 3A4. More than 80% of the P450 3A4 activity was lost after its incubation with 4-ipomeanol at the concentration of 75 microM in 12 min. The inactivation was characterized by a rate of inactivation (kinact) of 0.15 min(-1) and by an inactivation potency (KI) of 20 microM. In addition, the inhibition of P450 3A4 by 4-ipomeanol was NADPH-dependent and irreversible. Glutathione, catalase, and superoxide dismutase failed to protect P450 3A4 from inactivation by 4-ipomeanol. The presence of testosterone, a substrate of P450 3A4, protected the enzyme from inactivation. The estimated partition ratio of the inactivation was approximately 257. Covalent binding studies demonstrated that reactive metabolites of 4-ipomeanol modified P450 3A4 but not P450 reductase (EC 1.6.2.4). The stoichiometry of binding between reactive metabolites of radiolabeled 4-ipomeanol and P450 3A4 was approximately 1.5:1. In addition to P450 3A4, reactive metabolites of 4-ipomeanol were found to covalently bind to other proteins. 4-Ipomeanol failed to inactivate P450 1A2 in human liver microsomes. In conclusion, 4-ipomeanol irreversibly inhibited P450 3A4, and it was characterized as a mechanism-based inactivator of P450 3A4. This finding facilitates the understanding of the mechanism of bioactivation of 4-ipomeanol by human hepatic enzymes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967002     DOI: 10.1021/tx034143l

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  5 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol.

Authors:  Aaron M Teitelbaum; Matthew G McDonald; John P Kowalski; Oliver T Parkinson; Michele Scian; Dale Whittington; Katharina Roellecke; Helmut Hanenberg; Constanze Wiek; Allan E Rettie
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

Review 3.  Reactive metabolites in the biotransformation of molecules containing a furan ring.

Authors:  Lisa A Peterson
Journal:  Chem Res Toxicol       Date:  2012-10-24       Impact factor: 3.739

4.  A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2.

Authors:  Jiawang Liu; Peter T Pham; Elena V Skripnikova; Shilong Zheng; La'nese J Lovings; Yuji Wang; Navneet Goyal; Sydni M Bellow; Lydia M Mensah; Amari J Chatters; Melyssa R Bratton; Thomas E Wiese; Ming Zhao; Guangdi Wang; Maryam Foroozesh
Journal:  J Med Chem       Date:  2015-08-10       Impact factor: 7.446

5.  Synthesis and evaluation of a 18F-labeled 4-ipomeanol as an imaging agent for CYP4B1 gene prodrug activation therapy.

Authors:  Byung Seok Moon; Su Jin Jang; Sung Joo Kim; Tae Sup Lee; Dae Yoon Chi; Byung Chul Lee; Joo Hyun Kang; Sang Eun Kim
Journal:  Cancer Biother Radiopharm       Date:  2013-05-19       Impact factor: 3.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.